Protection against Loss of Innate Defenses in Adulthood by Low Advanced Glycation End Products (AGE) Intake: Role of the Antiinflammatory AGE Receptor-1

Vlassara, Helen; Cai, Weiping; Goodman, Susan; Pyzik, Renata; Yong, Angie; Xue, Chunyu; Zhu, Li; Neade, Tina; Beeri, Michal Schnaider; Silverman, Jeremy M.; Ferrucci, Luigi; Tansman, Laurie; Striker, Gary E.; Uribarri, Jaime

doi:10.1210/jc.2009-0089

Cited by 203 publications

(331 citation statements)

References 41 publications

Supporting

Mentioning

308

Contrasting

Unclassified

Order By: Relevance

“…We previously found that AGEs and OS increase and innate antioxidant defenses decrease with age (23). Because the mean age of the cohort was 65 years, we compared the responses to SC and CC in patients aged ,65 years with those aged .65 years.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of Sevelamer Carbonate on Advanced Glycation End Products and Antioxidant/Pro-Oxidant Status in Patients with Diabetic Kidney Disease

Yubero‐Serrano

Woodward

Poretsky³

et al. 2015

Clinical Journal of the American Society of Nephrology

Self Cite

View full text Add to dashboard Cite

Background and objectives The primary goals were to re-examine whether sevelamer carbonate (SC) reduces advanced glycation end products (AGEs) (methylglyoxal and carboxymethyllysine [CML]), increases antioxidant defenses, reduces pro-oxidants, and improves hemoglobin A1c (HbA1c) in patients with type 2 diabetes mellitus (T2DM) and diabetic kidney disease (DKD). Secondary goals examined albuminuria, age, race, sex, and metformin prescription.Design, setting, participants, & measurements This two-center, randomized, intention-to-treat, open-label study evaluated 117 patients with T2DM (HbA1c .6.5%) and stages 2-4 DKD (urinary albumin/creatinine ratio $200 mg/g) treated with SC (1600 mg) or calcium carbonate (1200 mg), three times a day, without changing medications or diet. Statistical analyses used linear mixed models adjusted for randomization levels. Preselected subgroup analyses of sex, race, age, and metformin were conducted.Results SC lowered serum methylglyoxal (95% confidence interval [CI], 20.72 to 20.29; P,0.001), serum CML (95% CI, 25.08 to 21.35; P#0.001), and intracellular CML (95% CI, 21.63 to 20.28; P=0.01). SC increased anti-inflammatory defenses, including nuclear factor like-2 (95% CI, 0.58 to 1.29; P=0.001), AGE receptor 1 (95% CI, 0.23 to 0.96; P=0.001), NAD-dependent deacetylase sirtuin-1 (95% CI, 0.20 to 0.86; P=0.002), and estrogen receptor a (95% CI, 1.38 to 2.73; P #0.001). SC also decreased proinflammatory factors such as TNF receptor 1 (95% CI, 21.56 to 20.72; P#0.001) and the receptor for AGEs (95% CI, 20.58 to 1.53; P#0.001). There were no differences in HbA1c, GFR, or albuminuria in the overall group. Subanalyses showed that SC lowered HbA1c in women (95% CI, 21.71 to 20.27; P=0.01, interaction P=0.002), and reduced albuminuria in those aged ,65 years (95% CI, 21.15 to 20.07; P=0.03, interaction P=0.02) and non-Caucasians (95% CI, 21.11 to 20.22; P=0.003, interaction P#0.001), whereas albuminuria increased after SC and calcium carbonate in Caucasians.Conclusions SC reduced circulating and cellular AGEs, increased antioxidants, and decreased pro-oxidants, but did not change HbA1c or the albumin/creatinine ratio overall in patients with T2DM and DKD. Because subanalyses revealed that SC may reduce HbA1c and albuminuria in some patients with T2DM with DKD, further studies may be warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

“…These included ACR, GFR, plasma HbA1c and fibroblast growth factor 23 Compliance was checked by pill count on a weekly basis. A research coordinator contacted patients at least weekly.…”

Section: Methodsmentioning

confidence: 99%

Effects of Sevelamer Carbonate on Advanced Glycation End Products and Antioxidant/Pro-Oxidant Status in Patients with Diabetic Kidney Disease

Yubero‐Serrano

Woodward

Poretsky³

et al. 2015

Clinical Journal of the American Society of Nephrology

Self Cite

View full text Add to dashboard Cite

show abstract

“…116 Although data in humans are limited, levels of proinflammatory factors are higher in patients with advanced CKD 117,118 as well as mice, 119 and a cascade of chemokine production and activation of proinflammatory factors likely lead to interstitial fibrosis, CKD, and distant-organ injury. 112,113,120 Reactive oxygen species (ROS) and advanced glycation end products (AGEs) increase with age, and levels of the antiinflammatory AGE receptor AGER1, which binds and quenches excess AGEs and ROS and inactivates the proinflammatory receptor RAGE, 121,122 are reduced under chronic oxidative conditions such as aging, CKD, or type 2 diabetes. 122 In mouse studies, RAGE induces ROS and superoxide in diabetic mitochondria, 123 and the severity of AKI depends on a functioning endoplasmic reticulum stress pathway and preexisting levels of ROS.…”

Section: Mechanisms Underlying Akimentioning

confidence: 99%

Acute Kidney Injury in Older Adults

Anderson¹,

Eldadah²,

Halter³

et al. 2011

Journal of the American Society of Nephrology

179

134

View full text Add to dashboard Cite

“…The notion that low-dAGE intake reduced markers of oxidative stress and inflammation, not only in patients with diabetes [11] or kidney disease [12,13], but also in healthy subjects [14], suggested that avoidance of dAGE-rich food could help in ameliorate chronic pathological conditions and in maintaining the healthy ageing status.…”

Section: Introductionmentioning

confidence: 99%

Advanced Glycation End Products (Ages) in Food: Focusing on Mediterranean Pasta

Abate¹,

Delbarba²,

Marziano³

et al. 2015

J Nutr Food Sci

View full text Add to dashboard Cite

Advanced glycation end products, also known as glycotoxins, are a diverse group of highly oxidant compounds with pathogenic significance in aged-chronic disease, including diabetes, cardiovascular disease and neurodegenerative disease. They are produced physiologically in the body when reducing sugar binds to a free amino acid group of macromolecules. Thus conditions such as hyperglycemia and/or oxidative stress can favor AGE product formation, contributing to ageing processes and the exacerbation of pathological states. Beside endogenous AGEs, dietary AGE intake contributes significantly to the body AGE pool. It assumes that if dietary AGE intake gets lower, any chronic disease, such as diabetes and cardiovascular disease can be ameliorated, and even cured. For this reason, recently great attention has been made on the identification and quantification of AGE products in the consumed foods. Here we reviewed some knowledge, found in literature, concerning the formation of AGEs in food, their gastrointestinal absorption, and their toxic effects. In addition original data on AGE content in the Mediterranean pasta was discussed in relation to their production processes and cooking time.

show abstract

Protection against Loss of Innate Defenses in Adulthood by Low Advanced Glycation End Products (AGE) Intake: Role of the Antiinflammatory AGE Receptor-1

Abstract: Reduction of AGEs in normal diets may lower oxidant stress/inflammation and restore levels of AGER1, an antioxidant, in healthy and aging subjects and CKD-3 patients. AGE intake has implications for health outcomes and costs and warrants further testing.

Cited by 203 publications

References 41 publications

Effects of Sevelamer Carbonate on Advanced Glycation End Products and Antioxidant/Pro-Oxidant Status in Patients with Diabetic Kidney Disease

Effects of Sevelamer Carbonate on Advanced Glycation End Products and Antioxidant/Pro-Oxidant Status in Patients with Diabetic Kidney Disease

Acute Kidney Injury in Older Adults

Advanced Glycation End Products (Ages) in Food: Focusing on Mediterranean Pasta

Contact Info

Product

Resources

About